EUVIMEDEUVIMED entdecken
Open Access

RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway

Shigui Xing, Dongbing Li, Qi Zhao

Aging · 2024

DOI: 10.18632/aging.206096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Shigui Xing und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanjing Gaochun People’s Hospital, Nanjing 211300, Jiangsu, China. Hauptthemen laut MEDLINE: Ribosomal Proteins, Adenocarcinoma of Lung, Proto-Oncogene Proteins c-mdm2, Biomarkers, Tumor. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ribosomal ProteinsAdenocarcinoma of LungProto-Oncogene Proteins c-mdm2Biomarkers, TumorTumor Suppressor Protein p53Lung NeoplasmsSignal TransductionHumansPrognosisFemaleMaleMiddle AgedCell Line, TumorGene Expression Regulation, NeoplasticAnimalsCell ProliferationMiceAged

Stichwörter der Autor:innen

MDM2/P53RPL22L1biomarkerimmune infiltrationlung adenocarcinomaprognosis

Substanzen

Ribosomal ProteinsProto-Oncogene Proteins c-mdm2Biomarkers, TumorTumor Suppressor Protein p53MDM2 protein, humanTP53 protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nanjing Gaochun People’s Hospital, Nanjing 211300, Jiangsu, China.
  • Scientific Research Center, Beijing ChosenMed Clinical Laboratory Co., Ltd., Beijing 100176, China.
  • Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, Jiangsu, China.

Zitieren

APA

Xing, S., Li, D., & Zhao, Q. (2024). RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway. Aging. https://doi.org/10.18632/aging.206096

Vancouver

Xing S, Li D, Zhao Q. RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway. Aging. 2024. doi:10.18632/aging.206096

BibTeX
@article{Xing2024,
  author = {Xing, Shigui and Li, Dongbing and Zhao, Qi},
  title = {RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.206096}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche